Skip to content

US · CUPR · BIOTECHNOLOGY

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) intrinsic value and stock valuation

$1.41as of 2026-11-21 · Mkt cap 8.9M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares DCF and intrinsic value

InvestorsCraft values CUPR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CUPR’s statements →

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Singapore, CE 169201 cuprina.com.sg

How the business is doing

Fiscal 2021–2025, USD

Revenue
$50K
20212025
Net income
-$-4.67M
20212025
Free cash flow
-$-9.19M
20212025
Total equity
$5.06M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$50K$50K$100K$60K$60K
Operating income-$-4.57M-$-1.65M-$-1.07M-$-1.18M-$-550K
Net income-$-4.67M-$-1.56M-$-1.12M-$-1.09M-$-520K
EPSd-$-1.82M-$-573.53K-$-411.76K-$-425.78K-$-203.13K
Operating cash flow-$-9.13M-$-1.24M-$-1.54M-$-1.85M-$-220K
Capital expenditure-$-60K-$-20K-$-70K-$-20K-$0.00
Free cash flow-$-9.19M-$-1.26M-$-1.61M-$-1.87M-$-220K
Total assets$8.5M$1.75M$1.59M$1.44M$950K
Total debt$480K$250K$120K$180K$170K
Net debt-$-2.63M$140K$90K-$-380K-$-600K
Total equity$5.06M-$-4.46M-$-2.9M-$-1.78M-$-680K
Cash and short-term investments$3.12M$120K$40K$560K$770K
Income statement
20252024202320222021
Revenue$50K$50K$100K$60K$60K
Cost of revenue$50K$50K$60K$40K$40K
Gross profit-$0.00-$0.00$40K$20K$20K
Research and development expenses$230K$240K$170K$290K$280K
Selling, general and administrative expenses$4.39M$1.27M$830K$830K$250K
Other expenses-$-50K$130K$100K$70K$50K
Operating expenses$4.57M$1.64M$1.1M$1.2M$580K
Cost and expenses$4.62M$1.69M$1.17M$1.23M$610K
Interest income$30K$0.00$0.00$0.00$0.00
Interest expense$10K$40K$60K$0.00$0.00
Depreciation and amortization$40K$40K$40K$30K$30K
Ebitda-$-4.56M-$-1.43M-$-990K-$-1.06M-$-490K
Operating income-$-4.57M-$-1.65M-$-1.07M-$-1.18M-$-550K
Total other income/expenses, net-$-110K$140K-$-20K$90K$30K
Income before tax-$-4.67M-$-1.51M-$-1.09M-$-1.09M-$-520K
Income tax expense$0.00$50K$30K$10K$0.00
Net income-$-4.67M-$-1.56M-$-1.12M-$-1.09M-$-520K
Weighted average shares outstanding$2.56M$2.72M$2.72M$2.56M$2.56M
Weighted average diluted shares outstanding$2.56M$2.72M$2.72M$2.56M$2.56M
Balance sheet
20252024202320222021
Cash and short-term investments$3.12M$120K$40K$560K$770K
Net receivables$260K$120K$210K$440K$20K
Inventory$0.00$0.00$10K$10K$0.00
Total current assets$7.33M$1.66M$1.44M$1.27M$810K
Property, plant and equipment, net$390K$90K$150K$160K$140K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$10K$0.00
Total non-current assets$1.17M$90K$150K$170K$140K
Total assets$8.5M$1.75M$1.59M$1.44M$950K
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$150K$90K$60K$60K$40K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.12M$6.04M$4.43M$3.09M$1.51M
Long-term debt$330K$160K$60K$120K$130K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$330K$160K$60K$120K$130K
Capital lease obligations$320K$40K$80K$120K$90K
Total liabilities$3.45M$6.2M$4.48M$3.21M$1.64M
Common stock$30K$20K$20K$20K$20K
Retained earnings-$-9.23M-$-4.56M-$-3M-$-1.88M-$-790K
Accumulated other comprehensive income (loss)$350K-$0.00$0.00-$0.00$0.00
Total equity$5.06M-$-4.46M-$-2.9M-$-1.78M-$-680K
Total investments$0.00$0.00$0.00$10K$0.00
Total debt$480K$250K$120K$180K$170K
Net debt-$-2.63M$140K$90K-$-380K-$-600K
Cash flow statement
20252024202320222021
Net income-$-4.67M-$-1.56M-$-1.12M-$-1.09M-$-520K
Depreciation and amortization$40K$40K$40K$30K$30K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-4.7M$230K-$-520K-$-810K$270K
Accounts receivable$10K$20K-$-40K-$-40K-$-20K
Inventory$0.00$0.00-$0.00-$-10K$0.00
Accounts payable-$0.00$0.00$0.00-$0.00-$0.00
Net cash provided by operating activities-$-9.13M-$-1.24M-$-1.54M-$-1.85M-$-220K
Investments in property, plant and equipment-$-60K-$-20K-$-70K-$-20K-$0.00
Acquisitions, net$0.00$0.00$0.00-$-20K$0.00
Net cash used for investing activities-$-60K-$-20K-$-70K-$-30K-$0.00
Common stock issued$17.6M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.2M$1.34M$1.08M$1.68M$990K
Net change in cash$3M$80K-$-530K-$-200K$770K
Cash at end of period$3.12M$120K$40K$560K$770K
Operating cash flow-$-9.13M-$-1.24M-$-1.54M-$-1.85M-$-220K
Capital expenditure-$-60K-$-20K-$-70K-$-20K-$0.00
Free cash flow-$-9.19M-$-1.26M-$-1.61M-$-1.87M-$-220K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

        Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.

        CEO
        Yong Qi Quek
        Employees
        10
        Beta
        -0.38

        Explore

        Frequently asked questions

        What is the intrinsic value of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)?

        InvestorsCraft does not currently publish an intrinsic value for CUPR. How the IC value is calculated.

        Is CUPR undervalued?

        InvestorsCraft does not publish an undervaluation signal for CUPR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.